Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib

by Ronan Swords, Devalingam Mahalingam, Swaminathan Padmanabhan, Jennifer Carew, Francis Giles
Published 2009-03-01

Effects of clinically relevant MPL mutations in the transmembrane domain revealed at the atomic level through computational modeling.

by Tai-Sung Lee, Hagop Kantarjian, Wanlong Ma, Chen-Hsiung Yeh, Francis Giles, Maher Albitar
Published 2011-01-01

Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (...

by Young Kwang Chae, Ayush Arya, Wade Iams, Marcelo R. Cruz, Sunandana Chandra, Jaehyuk Choi, Francis Giles
Published 2018-05-01

The Novel Oral BET-CBP/p300 Dual Inhibitor NEO2734 Is Highly Effective in Eradicating Acute Myeloid Leukemia Blasts and Stem/Progenitor Cells

by Noortje van Gils, Tania Martiañez Canales, Eline Vermue, Arjo Rutten, Fedor Denkers, Tiem van der Deure, Gert J. Ossenkoppele, Francis Giles, Linda Smit
Published 2021-08-01

JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasms.

by Wanlong Ma, Hagop Kantarjian, Xi Zhang, Xiuqiang Wang, Zhong Zhang, Chen-Hsiung Yeh, Susan O'Brien, Francis Giles, Jean Marie Bruey, Maher Albitar
Published 2010-01-01

Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

by Robert J. Kreitman, Claire Dearden, Pier Luigi Zinzani, Julio Delgado, Tadeusz Robak, Philipp D. le Coutre, Bjørn T. Gjertsen, Xavier Troussard, Gail J. Roboz, Lionel Karlin, Douglas E. Gladstone, Nataliya Kuptsova-Clarkson, Shiyao Liu, Priti Patel, Federico Rotolo, Emmanuel Mitry, Ira Pastan, Francis Giles, the Study 1053 investigators
Published 2021-02-01